Ikena Oncology, Inc. (IKNA)


-0.19 (-4.24%)
Symbol IKNA
Price $4.29
Beta 0.000
Volume Avg. 0.09M
Market Cap 155.545M
Shares () -
52 Week Range 1.94-11.79
1y Target Est -
DCF Unlevered IKNA DCF ->
DCF Levered IKNA LDCF ->
ROE -28.27% Sell
ROA -27.23% Sell
Operating Margin -
Debt / Equity 19.95% Neutral
P/E 5.36 Buy
P/B 0.98 Buy


Consensus EPS

Upgrades & Downgrades

Latest IKNA news

Dr. Mark Manfredi
NASDAQ Global Market

Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.